Elven

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elven

Property Description
Active Ingredient Betahistine (Dihydrochloride)
Form Oral tablets, Oral solution
Pharmacological Class Antivertigo Agent, Histamine Analogue
General Purpose Symptomatic relief of disequilibrium and vertigo
Origin Synthetic compound

What Type of Medicine is Elven and What is its Composition?

Elven is a prescription-only antivertigo agent that contains the synthetic active ingredient, Betahistine, most commonly supplied as Betahistine dihydrochloride. It is a single-ingredient product classified pharmacologically as a histamine analogue and a member of the aminoalkylpyridine chemical group. Elven is one of the globally recognized trade names for this formulation, and is primarily marketed to adult patients with balance disorders. As an oral medicine, it is available in solid form as tablets or as an oral solution.

This classification is critical because Betahistine is structurally distinct from older, centrally acting antihistamines sometimes used for dizziness. This compound is utilized for addressing vestibular function issues, serving as a specialized pharmaceutical option designed for inner ear-related balance problems.


Is Betahistine a Histamine Analogue and What Does it Generally Do?

Yes, Betahistine is a histamine analogue, meaning its structure is similar to the body's natural histamine, which allows it to modulate the body's balance system. The general therapeutic purpose of Elven is to provide symptomatic relief for the persistent sensations of disequilibrium, such as severe spinning (vertigo) and dizziness, which often originate in the inner ear.

Elven acts by stabilizing and correcting signals related to the vestibular system, making it a specialized choice for balance disorders. Its function is primarily focused on promoting the natural process of central vestibular compensation and improving inner ear circulation, helping the body manage disruptive balance signals.

Regulatory References

  1. EMA

What side effects are possible with Elven?

Possible Side Effects and Safety Information

The safety profile for Elven (Betahistine) is documented through regulatory sources, which classify adverse reactions based on frequency and affected physiological systems. This information is descriptive and not intended as clinical advice.

Adverse Reaction Classification

Official labeling classifies adverse reactions into defined frequency categories:

  • Common (ge 1/100 to < 1/10): Reactions frequently documented include Nausea, Dyspepsia (indigestion), and Headache.
  • Not Known (Cannot be estimated from available data): This category includes certain gastrointestinal complaints like Vomiting, Abdominal distension, and more serious events such as systemic Hypersensitivity reactions, including Anaphylaxis, and specific cutaneous reactions (e.g., Urticaria, Angioneurotic oedema).

Reactions are grouped by System-Organ-Class, primarily affecting the Gastrointestinal and Nervous Systems, with less frequent reports involving the Immune System and Skin.

Serious Safety Considerations

Rare but serious adverse reactions documented in regulatory sources include the potential for Anaphylaxis and, in rare instances, Convulsions (seizures).

Population and Constraint Notes

The regulatory safety profile includes restrictions for specific groups and conditions:

  • Contraindication: Elven is contraindicated in patients with Phaeochromocytoma.
  • Age Restriction: Use is not recommended in the paediatric population (under 18 years) due to insufficient efficacy and safety data.
  • Cautions: Caution is officially advised for patients with a history of peptic ulceration or bronchial asthma.

Mild gastrointestinal complaints are noted to be normally dealt with by taking the dose during meals, a time-related safety pattern documented in labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents define an overdose of Lisdexamfetamine Dimesylate (Elven/Vyvanse) as a serious medical event resulting from acute or chronic over-intoxication. The presentation involves severe central nervous system (CNS) and cardiovascular overstimulation.

Overdose Manifestation Regulator-Documented Outcomes
CNS Stimulation Agitation, hyperactive reflexes, restlessness, panic, confusion, and hyperthermia (abnormally high body temperature). Late-stage effects may include seizures, psychosis, and coma.
Cardiovascular Effects Tachycardia (rapid heartbeat), arrhythmias, hypertension, and potentially life-threatening outcomes such as stroke, myocardial infarction, or cardiovascular collapse.
Systemic Risk Serotonin Syndrome and rhabdomyolysis (muscle breakdown) are documented severe risks in overdose situations.

Immediate Actions and Emergency Response

The official labeling mandates that individuals seek emergency medical attention immediately if an overdose is suspected. This is required due to the potential for life-threatening complications. Treatment is specified as symptomatic and supportive, and the official regulatory documents confirm that no specific antidote is known for acute overdose. Monitoring of vital signs and intensive supportive care are necessary. Patients with severe renal impairment are noted to have a potential for prolonged and exacerbated overdose effects.

Therapeutic Uses of Elven

What Elven Treats: Main Uses and Benefits

Elven (lisdexamfetamine dimesylate) is commonly used to help with the management of symptoms associated with specific conditions characterized by periods of heightened symptoms. The medication is primarily applied in addressing Attention Deficit Hyperactivity Disorder (ADHD) in adults and children aged six years and older, as well as moderate to severe Binge Eating Disorder (BED) in adults.

In these scenarios, the therapy supports patients during difficult episodes by easing distress and assists with maintaining functional stability.

The medication is intended to assist with addressing symptom clusters related to heightened physiological activity and symptoms that interfere with daily functioning, such as those that affect attention, focus, and impulsive behaviors. For BED, it is considered relevant for easing symptoms linked to episodic manifestations. This is commonly used in clinical settings that involve acute or unstable symptom patterns. The therapy contributes to improved comfort during periods of heightened symptoms and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Symptoms that interfere with daily functioning

Eligibility and Restrictions for Use

Who Can and Cannot Use Elven?

The eligibility profile for Elven (Betahistine) is strictly governed by regulatory labeling that defines absolute exclusions and conditional use populations.


Absolute Contraindications

Elven is contraindicated and must not be used by patients diagnosed with phaeochromocytoma (a specific adrenal gland tumor) or those with a documented hypersensitivity (allergy) to betahistine or any of its excipients.


Age and Special Populations

The medicine is approved for adults and generally permitted for the geriatric population, where post-marketing data suggests no routine dose adjustment is needed. However, Elven is not recommended for the pediatric population (under 18 years) due to insufficient data on efficacy and safety. Use is also not recommended during pregnancy or lactation unless clinically essential, as safety data in humans is inadequate.


Conditional Use and Monitoring

Patients with pre-existing conditions such as bronchial asthma or a history of peptic ulceration must be carefully monitored during treatment. Caution is also necessary for patients with severe hypotension or known allergic skin conditions. For patients with renal or hepatic impairment, use is conditional, though post-marketing experience indicates dose adjustment is typically not required.

What should I know about interactions with other medicines?

Elven can interact with a variety of other medicinal products, primarily through mechanisms involving certain liver enzymes and drug transporters. Awareness of these interactions is essential to maintain proper drug levels in the body.

Key Interaction Categories

Elven is a substrate for the cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) and OATP1B1/1B3 transporters. Therefore, co-administration with medicines that affect these systems can significantly alter the concentration of Elven in the blood.

  • Strong CYP3A4 Inhibitors: Co-administration with strong inhibitors of the CYP3A4 enzyme (e.g., ketoconazole) increases Elven exposure. This requires a mandatory dose reduction of Elven to mitigate the risk of elevated concentrations.
  • Strong CYP3A4 Inducers: Conversely, strong inducers of CYP3A4 (e.g., rifampin) substantially decrease Elven levels. This loss of drug concentration can reduce the efficacy of Elven, and co-administration with strong inducers is generally not recommended.
  • Transporter Inhibitors: Inhibitors of transporters like P-gp or OATP1B1/1B3 (e.g., cyclosporine, gemfibrozil) may also increase the systemic exposure of Elven and should be used with caution.

Interaction Restrictions

Certain combinations are classified as contraindicated due to the potential for highly significant changes in drug exposure. Clinicians must also ensure appropriate dose modifications are implemented for other use-with-caution combinations, particularly with strong metabolic enzyme inhibitors, to maintain the desired therapeutic window.

Mechanism of Action

How Elven Works — Mechanism of Action


Central Modulation via Histamine H3 Receptor Antagonism

The core mechanism involves acting as an antagonist at presynaptic Histamine H3 receptors (H3R) within the brainstem's Vestibular Nuclei. By blocking these inhibitory receptors, the drug functionally increases the release and turnover of endogenous histamine, a crucial neurotransmitter. This enhanced histaminergic signaling in the central balance pathways facilitates the process of central vestibular compensation, which is the brain's natural neuroplastic adjustment to modulate asymmetrical input signals.


Complementary Peripheral Vasodilation

The drug also demonstrates weak partial agonism at Histamine H1 receptors (H1R) located on the microvasculature of the inner ear. This action triggers localized vasodilation, leading to an increased supply of blood and oxygen to the cochlea and vestibular labyrinth. This complementary mechanism modifies the physiological environment of the sensory balance organs, which influences peripheral signal transmission dynamics.

Dosage and Administration Information

How to Use Elven: Administration Guidelines

Elven (betahistine) is used via the oral route. Its administration pattern is characterized by divided daily dosing and specific timing instructions relative to food intake. The use protocol is typically established as a long-term plan, which involves consistent adherence to the prescribed daily quantity and schedule.

Administration Parameters

Usage Component Standard Requirement
Route of Administration Oral administration only.
Dosing Schedule Total daily doses generally range from 24 mg up to a maximum recommended daily dose of 48 mg. Starting doses are often 8 mg or 16 mg.
Frequency Pattern The total daily dose is administered in 2 or 3 separate, equally spaced doses, rather than all at once.
Timing Instruction The tablets are taken with food or immediately after a meal to address known gastrointestinal constraints.

Procedural and Population Rules

  • Long-Term Protocol: Treatment is part of a long-term strategy and is continued under regular, periodic professional review to determine the necessity of ongoing therapy.
  • Missed Dose Handling: If a scheduled dose is missed, the standard procedure is to skip it. The regular dosing schedule is resumed by taking the next dose at the usual time; the next dose is not doubled to compensate.
  • Age-Specific Use: The medication is not recommended for use in children and adolescents under the age of 18, as there is insufficient data for administration in this population.

Recent Clinical Evidence

Elven: Recent Clinical Evidence

Clinical development for the investigational compound Elven (ELVN-001) has primarily focused on its use as a highly selective inhibitor in the treatment of specific hematologic malignancies. The most substantial clinical data relates to its evaluation in patients with Chronic Myeloid Leukemia (CML), particularly those who have failed, are refractory to, or are intolerant of prior tyrosine kinase inhibitors (TKIs), including those with the T315I mutation.


Clinical Findings in Chronic Myeloid Leukemia (CML)

Phase 1 clinical trial data for ELVN-001 suggested preliminary evidence of anti-CML activity. In a cohort of heavily pretreated CML patients, the drug was associated with a cumulative major molecular response (MMR) rate observed at 24 weeks. This response rate compares favorably with reported precedents from other approved BCR::ABL1 TKI Phase 1 trials in a similar patient population.


Safety Profile

Across multiple dose levels (up to 120 mg once daily) evaluated in the Phase 1 CML study, the compound demonstrated a generally favorable safety profile. The study reported that the substance was generally well-tolerated, with no dose reductions reported due to treatment-related adverse events. Furthermore, no significant non-hematologic treatment-related adverse events were observed, supporting its development potential as an option for patients with limitations to current TKI therapies.


Other Investigational Use

Another compound, ELVN-002, is in the early stages of investigation for the treatment of HER2 mutant non-small cell lung cancer (NSCLC). Current studies for this related drug are focused on determining its safety, tolerability, and pharmacokinetics in advanced stage solid tumors with HER2 abnormalities.

Frequently Asked Questions (FAQ)

Common questions about Elven (FAQ)

Q: Can Elven cause insomnia or change my sleep patterns?

A: Official regulatory documents do not specifically list insomnia or changes in sleep patterns as a common side effect of Elven. While the drug does act on the central nervous system, effects related to sleep are not listed as common or known adverse reactions in the official product information.

Q: Are there any specific vitamins or supplements that should not be taken with Elven?

A: No specific warnings are issued for common vitamins or standard supplements in the product information. However, regulatory caution is advised regarding co-administration with a class of medicines called Monoamine-Oxidase Inhibitors (MAOIs).

Q: Does Elven have any known interactions with alcohol?

A: While alcohol is not listed in the primary drug-drug interaction section of the official label, regulatory safety documentation has referenced an interaction with ethanol. This information should be considered when consuming alcohol.

Q: How long after starting Elven will I know if it's helping my condition?

A: Studies and official information indicate that Elven is intended for long-term use. Therefore, the full therapeutic effect may take time to develop, and studies often evaluate effectiveness over several months of continuous use.

Q: What should I do if the side effects from Elven are bothersome but not severe?

A: Official patient information often notes that mild gastrointestinal complaints, such as nausea, may be lessened by taking the medication with food. For other bothersome side effects, official guidance directs patients to seek professional advice.

Q: Is Elven a controlled substance or does it have a risk of dependence?

A: Official regulatory bodies do not classify Elven (Betahistine) as a controlled substance. It has not been officially associated with a risk of dependence or addiction.

Q: Can Elven affect blood pressure or heart rate?

A: Official labeling indicates caution is required for patients with severe low blood pressure, and it is strictly contraindicated (must not be used) in patients with phaeochromocytoma, a condition that can cause high blood pressure.

Q: What kind of research studies have been conducted on the effectiveness of Elven?

A: The effectiveness of Elven is detailed in regulatory documents based on clinical studies demonstrating its ability to facilitate the brain’s natural balance adjustment process (vestibular compensation). Research has shown it can help reduce the frequency and severity of vertigo attacks.

Q: What is the typical duration of treatment with Elven?

A: Treatment with Elven is typically considered a long-term protocol. The necessity of continuing therapy must be determined through regular, periodic professional review.

Q: Will stopping Elven suddenly cause any withdrawal-like symptoms?

A: Elven is rapidly broken down by the body. Due to the rapid clearance of the primary compound (half-life of about 3.5 hours), severe or prolonged withdrawal effects are not typically expected.

Q: How should Elven be stored to maintain its effectiveness?

A: Official guidance requires storage at temperatures generally not exceeding 30 C. The medication must be kept in a safe place, out of the sight and reach of children, to prevent accidental exposure.

Q: Does Elven interfere with the effectiveness of birth control pills?

A: The official product information does not include any specific warning or documented interaction stating that Elven interferes with the effectiveness of hormonal birth control pills. Clinical studies assessing this interaction have not been performed.

Q: Are there any rare but serious side effects of Elven that I should watch out for?

A: Serious adverse reactions documented in regulatory sources include the potential for systemic Hypersensitivity reactions, Anaphylaxis, and, in rare instances, Convulsions (seizures).

Q: What happens if I accidentally take two doses of Elven close together?

A: Symptoms of overdose are generally mild, often involving headache, nausea, or stomach discomfort. More serious effects, such as convulsions, have been reported with very high doses. If an overdose is suspected, official guidance advises seeking professional medical help.

Q: How long does Elven stay in your system after you stop taking it?

A: Elven is rapidly metabolized and its primary, inactive compound has an elimination half-life of about 3.5 hours. This means the substance is virtually cleared from the system and excreted in the urine within about 24 hours.

Q: Does Elven interact with herbal remedies like St. John's Wort?

A: Elven is metabolized by liver enzymes. Regulatory caution is given for medicines that strongly affect the CYP3A4 enzyme. If an herbal product is known to be a strong CYP3A4 inducer, this may potentially reduce Elven's efficacy.

Q: Can Elven affect mood or cause emotional changes?

A: Although the drug acts on the central nervous system, official regulatory documents do not list mood or emotional changes as a common, uncommon, or known side effect in the product information.

Q: Is there a specific time of day that is best for taking Elven?

A: The official guidance emphasizes that the total daily dose should be divided into 2 or 3 equally spaced doses, and each dose must be taken with food. The specific time of day (morning vs. evening) is not mandated, provided the schedule is consistent.

Q: Do I need to get regular blood tests while taking Elven?

A: The official product information from regulatory bodies does not mandate routine blood tests for monitoring liver, kidney, or drug levels as a requirement during treatment with Elven.

Q: Can Elven make my skin more sensitive to the sun?

A: Official documentation on skin-related side effects includes allergic reactions like hives and swelling. However, increased sun sensitivity (photosensitivity) is not listed as an adverse reaction in the regulatory product information.

Q: Can Elven cause changes in appetite or body weight?

A: Changes in appetite or body weight are not officially listed as a common, uncommon, or known side effect in the official regulatory labeling for Elven.

Q: Does Elven interact with common cold or flu medications?

A: The product information states that concurrent use with antihistamines is not recommended on the theoretical basis that it could reduce Elven's effectiveness, and many common cold and flu products contain antihistamines.

Q: Is it important to take Elven at the exact same time every day?

A: Regulatory guidance stresses the importance of taking the total daily dose in equally spaced doses and adhering to a consistent schedule. This consistency is important to maintain stable drug levels in the body for the most effective outcome.

Q: How can I tell if my condition is improving while using Elven?

A: Improvement would be assessed by observing a noticeable reduction in the frequency and severity of your primary symptoms, such as vertigo attacks and overall sensations of disequilibrium, which were the focus of clinical studies.

Q: Do pre-existing medical conditions affect how Elven works?

A: Official guidance indicates that caution and monitoring are advised for patients with a history of bronchial asthma or peptic ulceration. The medicine is strictly contraindicated in patients with phaeochromocytoma.

How should Elven be stored and disposed of?

How to Store and Dispose of ELVAN (lisdexamfetamine dimesylate)

ELVAN capsules must be stored at controlled room temperature between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C. To maintain product stability, the medication must be protected from light and moisture and kept in a tightly closed container.

Child Safety and Security

Due to its classification as a Schedule II controlled substance, ELVAN must be stored securely at all times and kept out of the reach of children to prevent misuse or accidental ingestion.

Official Disposal Requirements

Official instructions prioritize using a registered drug take-back program. If this option is not readily available, the FDA mandates that the unused product be flushed down the toilet immediately to eliminate the risk of accidental exposure. Disposal must be conducted in accordance with all local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Elven found in:

A-Z Index: